» Articles » PMID: 36231068

Transcriptome Changes in Glioma Cells Cultivated Under Conditions of Neurosphere Formation

Abstract

Glioma is the most common and heterogeneous primary brain tumor. The development of a new relevant preclinical models is necessary. As research moves from cultures of adherent gliomas to a more relevant model, neurospheres, it is necessary to understand the changes that cells undergo at the transcriptome level. In the present work, we used three patient-derived gliomas and two immortalized glioblastomas, while their cultivation was carried out under adherent culture and neurosphere (NS) conditions. When comparing the transcriptomes of monolayer (ML) and NS cell cultures, we used Enrichr genes sets enrichment analysis to describe transcription factors (TFs) and the pathways involved in the formation of glioma NS. It was observed that NS formation is accompanied by the activation of five common gliomas of TFs, SOX2, UBTF, NFE2L2, TCF3 and STAT3. The sets of transcripts controlled by TFs MYC and MAX were suppressed in NS. Upregulated genes are involved in the processes of the epithelial-mesenchymal transition, cancer stemness, invasion and migration of glioma cells. However, MYC/MAX-dependent downregulated genes are involved in translation, focal adhesion and apical junction. Furthermore, we found three EGFR and FGFR signaling feedback regulators common to all analyzed gliomas-SPRY4, ERRFI1, and RAB31-which can be used for creating new therapeutic strategies of suppressing the invasion and progression of gliomas.

Citing Articles

Integrated pan-cancer and scRNA-seq analyses identify a prognostic coagulation-related gene signature associated with tumor microenvironment in lower-grade glioma.

Wen X, Bai S, Fang Z, Zhu W Discov Oncol. 2024; 15(1):256.

PMID: 38955935 PMC: 11219639. DOI: 10.1007/s12672-024-01114-w.


Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas.

Onciul R, Brehar F, Toader C, Covache-Busuioc R, Glavan L, Bratu B Curr Issues Mol Biol. 2024; 46(3):2402-2443.

PMID: 38534769 PMC: 10969338. DOI: 10.3390/cimb46030153.


Development of a Single-Neurosphere Culture to Assess Radiation Toxicity and Pre-Clinical Cancer Combination Therapy Safety.

Pathak B, Lange T, Lampe K, Hollander E, Oria M, Murphy K Cancers (Basel). 2023; 15(20).

PMID: 37894283 PMC: 10605382. DOI: 10.3390/cancers15204916.


Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.

Schnoller L, Piehlmaier D, Weber P, Brix N, Fleischmann D, Nieto A Radiat Oncol. 2023; 18(1):51.

PMID: 36906590 PMC: 10007763. DOI: 10.1186/s13014-023-02241-4.

References
1.
Leblanc V, Trinh D, Aslanpour S, Hughes M, Livingstone D, Jin D . Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity. Cancer Cell. 2022; 40(4):379-392.e9. DOI: 10.1016/j.ccell.2022.02.016. View

2.
Reynolds B, Weiss S . Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science. 1992; 255(5052):1707-10. DOI: 10.1126/science.1553558. View

3.
Kresse N, Schroder H, Stein K, Wilkens L, Mawrin C, Sandalcioglu I . PLOD2 Is a Prognostic Marker in Glioblastoma That Modulates the Immune Microenvironment and Tumor Progression. Int J Mol Sci. 2022; 23(11). PMC: 9181500. DOI: 10.3390/ijms23116037. View

4.
Iser I, Pereira M, Lenz G, Wink M . The Epithelial-to-Mesenchymal Transition-Like Process in Glioblastoma: An Updated Systematic Review and In Silico Investigation. Med Res Rev. 2016; 37(2):271-313. DOI: 10.1002/med.21408. View

5.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View